Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pajares

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Oncotarget|February 22, 2018
Complement C4d-specific antibodies for the diagnosis of lung cancerDaniel Ajona, Marcin Okrój, María J Pajares, et al.
Oncotarget|March 19, 2016
Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patientsMaria Villalba, Angel Diaz-Lagares, Miriam Redrado, et al.
Molecular Cancer Research : MCR|February 26, 2014
TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLCJackeline Agorreta, Jianting Hu, Dongxia Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2011
Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistanceMariano Ponz-Sarvisé, Paul A Nguewa, María J Pajares, et al.
Journal of the National Cancer Institute|August 14, 2013
Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancerDaniel Ajona, María J Pajares, Leticia Corrales, et al.
American Journal of Respiratory and Critical Care Medicine|February 11, 2015
Improving selection criteria for lung cancer screening. The potential role of emphysemaPablo Sanchez-Salcedo, David O Wilson, Juan P de-Torres, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2012
Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lungMaría J Pajares, Jackeline Agorreta, Marta Larrayoz, et al.
American Journal of Respiratory and Critical Care Medicine|January 13, 2018
Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated EffectsDaniel Ajona, Carolina Zandueta, Leticia Corrales, et al.
BMC Genomics|October 8, 2015
Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterationsAnder Aramburu, Isabel Zudaire, María J Pajares, et al.
The Journal of Pathology|May 15, 2018
A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patientsElena Martínez-Terroba, Carmen Behrens, Fernando J de Miguel, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Oncotarget|February 22, 2018
Complement C4d-specific antibodies for the diagnosis of lung cancerDaniel Ajona, Marcin Okrój, María J Pajares, et al.
Oncotarget|March 19, 2016
Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patientsMaria Villalba, Angel Diaz-Lagares, Miriam Redrado, et al.
Molecular Cancer Research : MCR|February 26, 2014
TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLCJackeline Agorreta, Jianting Hu, Dongxia Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2011
Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistanceMariano Ponz-Sarvisé, Paul A Nguewa, María J Pajares, et al.
Journal of the National Cancer Institute|August 14, 2013
Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancerDaniel Ajona, María J Pajares, Leticia Corrales, et al.
American Journal of Respiratory and Critical Care Medicine|February 11, 2015
Improving selection criteria for lung cancer screening. The potential role of emphysemaPablo Sanchez-Salcedo, David O Wilson, Juan P de-Torres, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2012
Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lungMaría J Pajares, Jackeline Agorreta, Marta Larrayoz, et al.
American Journal of Respiratory and Critical Care Medicine|January 13, 2018
Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated EffectsDaniel Ajona, Carolina Zandueta, Leticia Corrales, et al.
BMC Genomics|October 8, 2015
Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterationsAnder Aramburu, Isabel Zudaire, María J Pajares, et al.
The Journal of Pathology|May 15, 2018
A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patientsElena Martínez-Terroba, Carmen Behrens, Fernando J de Miguel, et al.
Pageof 6